In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.
Different fusion oncogenes in acute myeloid leukemia (AML) have distinct clinical and laboratory features suggesting different modes of malignant transformation. Here we compare the in vitro effects of representatives of 4 major groups of AML fusion oncogenes on primary human CD34+ cells. As expected from their clinical similarities, MLL-AF9 and NUP98-HOXA9 had very similar effects in vitro. They both caused erythroid hyperplasia and a clear block in erythroid and myeloid maturation. On the other hand, AML1-ETO and PML-RARA had only modest effects on myeloid and erythroid differentiation. All oncogenes except PML-RARA caused a dramatic increase in long-term proliferation and self-renewal. Gene expression profiling revealed two distinct temporal patterns of gene deregulation. Gene deregulation by MLL-AF9 and NUP98-HOXA9 peaked 3 days after transduction. In contrast, the vast majority of gene deregulation by AML1-ETO and PML-RARA occurred within 6 hours, followed by a dramatic drop in the numbers of deregulated genes. Interestingly, the p53 inhibitor MDM2 was upregulated by AML1-ETO at 6 hours. Nutlin-3, an inhibitor of the interaction between MDM2 and p53, specifically inhibited the proliferation and self-renewal of primary human CD34+ cells transduced with AML1-ETO, suggesting that MDM2 upregulation plays a role in cell transformation by AML1-ETO. These data show that differences among AML fusion oncogenes can be recapitulated in vitro using primary human CD34+ cells and that early gene expression profiling in these cells can reveal potential drug targets in AML.
Abdul-Nabi
Anmaar M
AM
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Yassin
Enas R
ER
Varghese
Nobish
N
Deshmukh
Hrishikesh
H
Yaseen
Nabeel R
NR
D018952:Antigens, CD34 / Q000378:metabolism*; D002454:Cell Differentiation / Q000235:genetics; D002460:Cell Line; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D050596:Oncogene Fusion; D009857:Oncogenes / Q000235:genetics*; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics; D013997:Time Factors
D018952:Antigens, CD34; D051736:Proto-Oncogene Proteins c-mdm2
Nat Med. 2002 Jul;8(7):743-50
12091906
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4016-21
15731354
Mol Cancer Res. 2003 Dec;1(14):1001-8
14707283
Science. 2007 Apr 27;316(5824):600-4
17463288
Trends Cell Biol. 2005 Sep;15(9):494-501
16084092
Blood. 2005 Aug 15;106(4):1189-98
15878973
Blood. 2008 Feb 15;111(4):2190-9
17975013
N Engl J Med. 2004 Apr 15;350(16):1605-16
15084693
Leukemia. 2001 Nov;15(11):1689-95
11681408
Oncogene. 2008 Jun 19;27(27):3765-79
18264136
Oncogene. 2005 Aug 29;24(37):5693-700
16123802
Leukemia. 2002 Feb;16(2):186-95
11840284
Blood. 2002 Jan 1;99(1):15-23
11756147
Curr Opin Hematol. 2007 Mar;14(2):85-9
17255784
Blood. 2005 Nov 1;106(9):3150-9
16014563
Blood. 2003 Sep 1;102(5):1857-65
12750176
Leukemia. 2009 Jul;23(7):1303-10
19225539
Cell. 1998 Mar 20;92(6):713-23
9529248
Clin Cancer Res. 1998 Dec;4(12):3051-62
9865920
Cancer Res. 2006 Dec 15;66(24):11781-91
17178874
Cancer Lett. 2007 Jun 28;251(2):179-86
17125917
Cell. 1998 Mar 20;92(6):725-34
9529249
Science. 2004 Feb 6;303(5659):844-8
14704432
N Engl J Med. 2004 Apr 15;350(16):1617-28
15084694
J Interferon Cytokine Res. 2007 Jul;27(7):543-52
17651015
Leukemia. 2007 Aug;21(8):1638-47
17554387
Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
16493418
Leukemia. 2004 Jul;18(7):1238-45
15152269
Haematologica. 2009 Jul;94(7):984-93
19535349
Annu Rev Pharmacol Toxicol. 2009;49:223-41
18834305
Cancer Cell. 2008 Jun;13(6):483-95
18538732
Methods Mol Biol. 2009;538:263-85
19277588
Int J Biochem Cell Biol. 2007;39(6):1063-70
17468032
Blood. 2000 Aug 15;96(4):1531-7
10942402
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10008-13
12105272
Blood. 2006 Jul 15;108(2):685-96
16597596
Cancer Res. 2009 Feb 1;69(3):1109-16
19155294
Oncogene. 2002 May 13;21(21):3475-95
12032783
Nat Genet. 2004 Oct;36(10):1084-9
15361874
Blood. 1998 Oct 1;92(7):2322-33
9746770
Leukemia. 2009 Aug;23(8):1490-9
19262598
Leukemia. 2006 Apr;20(4):696-706
16467868
Genes Chromosomes Cancer. 2002 Apr;33(4):331-45
11921269
Leukemia. 2006 Feb;20(2):218-23
16341046
Arch Pathol Lab Med. 2008 Nov;132(11):1835-7
18976025
Cancer Res. 2006 Jul 1;66(13):6628-37
16818636
Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1030-5
16418266
Semin Cell Dev Biol. 2008 Jun;19(3):294-308
18343170
Cancer Res. 2006 Mar 15;66(6):2990-6
16540647
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
11309499
Blood. 2008 May 1;111(9):4668-80
18299449
Genes Chromosomes Cancer. 2003 Jun;37(2):149-58
12696063
Proc Natl Acad Sci U S A. 1990 May;87(9):3584-8
2333304
Science. 1999 Oct 15;286(5439):531-7
10521349
Blood. 2003 Oct 1;102(7):2395-402
12805060
Blood. 2006 Sep 1;108(5):1690-7
16670269
Cell. 2009 May 15;137(4):609-22
19450511
Blood. 2010 Jul 8;116(1):71-80
20404136
Science. 1997 Nov 7;278(5340):1059-64
9353180